Ascendis Pharma A/S
ASND
Positions held
Your positionsASND isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Ascendis Pharma operates in a competitive biotechnology sector with a strong focus on innovative therapies, positioning itself well against rivals.
- In Q2 2026, Ascendis Pharma reported a revenue increase of 38% compared to the prior quarter, reaching $339 million.
- The company's operating margin expanded to 65% in Q2 2026.
- The company's financial performance has shown significant volatility, with a negative trend in operating margins over the past year.
- Ascendis Pharma's net income was -481.447 million in 2023, reflecting ongoing financial challenges.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $14.65B | Enterprise value | $14.26B | Trailing P/E | 17.06 | Forward P/E | 20.68 |
| PEG | — | Price / book | 9.09 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | 114.7% | Earnings growth | — | Gross margin | 91.3% | Operating margin | 65.0% |
| Profit margin | 70.8% | ROE | 118.8% | ROA | 9.6% | Debt / equity | 0.31 |
| Current ratio | 2.99 | Free cash flow | $12.77M | Analyst recommendation | strong_buy | Mean target | $307.53 |
| 52w high | $282.15 | 52w low | $186.05 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $339M | $247M | $248M | $214M | $158M | — |
| Op margin | 65.0% | 10.1% | 2.6% | 5.1% | -33.5% | — |
| Net income | $207M | $629M | -$33.6M | -$61.0M | -$38.9M | — |
| Gross margin | 91.8% | 92.9% | 90.5% | 89.5% | 80.1% | — |
| Gross profit | $312M | $229M | $224M | $191M | $127M | — |
| Operating income | $220M | $24.8M | $6.4M | $11.0M | -$53.0M | — |
- Revenue +38% vs prior quarter ($339M vs $247M).
- Gross margin 91.8% (was 92.9% prior quarter).
- Operating margin expanded to 65%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $720M | $364M | $267M | $51.2M |
| Op margin | -18.9% | -76.7% | -170.8% | -1097.9% |
| Net income | -$228M | -$378M | -$481M | -$583M |
| Gross margin | 86.8% | 87.8% | 83.4% | 76.3% |
| Gross profit | $625M | $319M | $222M | $39.0M |
| Operating income | -$136M | -$279M | -$456M | -$562M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
2026-10-06 · Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
2026-10-05 · This Biotech’s Proprietary Platform Could Unlock Its Next Growth Phase
2026-09-21 · Ascendis Pharma (ASND) Authorizes $400M Share Buyback
2026-09-19 · Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs
2026-09-17 · Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?
2026-09-16 · BioMarin Stops Voxzogo Development for Noonan Syndrome
2026-09-16 · Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says
2026-09-15 · Ulta Beauty, Etsy upgraded: Wall Street's top analyst calls
2026-09-15 · Sector Update: Healthcare Stocks Fall Pre-Bell Tuesday
2026-09-15 · Sector Update: Healthcare
2026-09-15 · Raymond James Downgrades Ascendis Pharma to Outperform From Strong Buy
Price (daily)
Full chart · RSI · MACD · patterns